

# API's R&D PORTFOLIO

PRODUCT NAME	THERAPEUTIC CLASS	CAS nr.
<b>ACLIDINIUM</b> BROMIDE	Bronchodilator (COPD)	320345-99-1
<b>ALBUTEROL (SALBUTAMOL)</b> SULFATE	Bronchodilator (COPD)	51022-70-9
<b>ALDOXORUBICIN</b> HYDROCHLORIDE	Antineoplastic (Soft Tissue Sarcoma - STS)	1361563-03-2
<b>ALOGLIPTIN</b> BENZOATE	Antidiabetic (Type II)	850649-62-2
<b>APALUTAMIDE</b>	Antineoplastic (Prostate)	956104-40-8
<b>AZACITIDINE</b>	Antineoplastic (Leukemia)	320-67-2
<b>BARNIDIPINE</b> HYDROCHLORIDE	Antihypertensive	104757-53-1
<b>BEXAROTENE</b>	Antineoplastic (Skin)	153559-49-0
<b>BLONANSERIN</b>	Antipsychotic	132810-10-7
<b>CANGRELOR</b> TETRASODIUM	Antithrombotic	163706-36-3
<b>CRISABOROLE</b>	Atopic dermatitis	906673-24-3
<b>DANTROLENE</b> SODIUM	Antispastic	14663-23-1
<b>DECITABINE</b>	Antineoplastic (Leukemia)	2353-33-5
<b>EFINACONAZOLE</b>	Antimicotic (Onychomycosis)	164650-44-6
<b>ELAGOLIX</b> SODIUM	Anti-endometriosis	832720-36-2
<b>ENZALUTAMIDE</b>	Antineoplastic (Prostate)	915087-33-1
<b>EPINEPHRINE</b>	Antiallergic	51-43-4
<b>FENFLURAMINE</b> HYDROCHLORIDE	Antiepileptic (Dravet and Lennox-Gastaut Syndromes)	404-82-0
<b>FENRETINIDE</b>	Antineoplastic (Blood)	65646-68-6
<b>FIDAXOMICIN</b>	Antibiotic (Gastrointestinal)	873857-62-6
<b>FLUPENTIXOL</b> DIHYDROCHLORIDE	Antipsychotic	2413-38-9
<b>INDACATEROL</b> MALEATE	Bronchodilator (COPD)	753498-25-8
<b>IVABRADINE</b> HYDROCHLORIDE	Antianginal	148849-67-6
<b>LASMIDITAN</b> HEMISUCCINATE	Antimigraine	439239-92-6
<b>LEFAMULIN</b> ACETATE	Antibacterial (Lungs)	1350636-82-6
<b>LENVATINIB</b> MESYLATE	Antineoplastic (Kidney, Thyroid)	857890-39-2
<b>LETERMOVIR</b>	Antiviral (Cytomegalovirus)	917389-32-3
<b>LEVOMILNACIPRAN</b> HYDROCHLORIDE	Antidepressant	175131-60-9
<b>LEVOSIMENDAN</b>	Heart failure treatment	141505-33-1
<b>LIFITEGRAST</b>	Dry eye disease	1025967-78-5
<b>LURASIDONE</b> HYDROCHLORIDE	Antipsychotic	367514-88-3
<b>NINTEDANIB</b> ESYLATE	Antineoplastic (Lung)	656247-18-6
<b>OLAPARIB</b>	Antineoplastic (Breast, Ovary)	763113-22-0
<b>OSPEMIFENE</b>	Postmenopausal treatment	128607-22-7
<b>PIMAVANSERIN</b> TARTRATE	Anti-Parkinson	706782-28-7
<b>PITAVASTATIN</b> CALCIUM	Antilipemic	147526-32-7
<b>POMALIDOMIDE</b>	Antineoplastic (Blood)	19171-19-8

DISCLAIMER: These APIs are supplied solely: for performing the strictly necessary studies and trials aimed to the obtainment of an AIC or of a marketing authorization, according to Article 10 of directive 2001/83/CE, or for experimental purposes aimed to scientific innovation, or under an agreement or a contract for a co-development aimed to obtain a marketing authorization (dossiers). Any other use that may constitute a violation of any possible related exclusivity rights of the owner(s) of relevant European patents and/or relevant related national patents and/or supplementary protection certificates (SPC), is not allowed. In case of breach of this clause, you will keep us fully indemnified and harmless from any claims and consequences arising out of such use and breach.

<b>PRODUCT NAME</b>	<b>THERAPEUTIC CLASS</b>	<b>CAS nr.</b>
<b>PRISTINAMYCIN</b>	Antibacterial	8065-94-9
<b>ROTIGOTINE</b>	Anti-Parkinson	99755-59-6
<b>TAVABOROLE</b>	Antimicotic (Onychomycosis)	174671-46-6
<b>TEDUGLUTIDE</b>	Short Bowel Syndrome	197922-42-2
<b>THIOTEPA</b>	Antineoplastic (Breast, Ovary); Blood diseases	52-24-4
<b>TIOTROPIUM BROMIDE</b>	Bronchodilator (COPD)	136310-93-5
<b>TOFACITINIB CITRATE</b>	Antiarthritic	540737-29-9
<b>TOLVAPTAN</b>	Antihyponatremic	150683-30-0
<b>TRIFAROTENE</b>	Antiacne	895542-09-3
<b>UMECLIDINIUM BROMIDE</b>	Bronchodilator (COPD)	869113-09-7
<b>VENETOCLAX</b>	Antineoplastic (Leukemia - CLL)	1257044-40-8
<b>VILANTEROL TRIFENATATE</b>	Bronchodilator (COPD)	503070-58-4

DISCLAIMER: These APIs are supplied solely: for performing the strictly necessary studies and trials aimed to the obtainment of an AIC or of a marketing authorization, according to Article 10 of directive 2001/83/CE, or for experimental purposes aimed to scientific innovation, or under an agreement or a contract for a co-development aimed to obtain a marketing authorization (dossiers). Any other use that may constitute a violation of any possible related exclusivity rights of the owner(s) of relevant European patents and/or relevant related national patents and/or supplementary protection certificates (SPC), is not allowed. In case of breach of this clause, you will keep us fully indemnified and harmless from any claims and consequences arising out of such use and breach.

**PAGE 2 of 2**



**Olon S.p.A.**

Strada Rivoltana km. 6/7 20090 Rodano (Milan) - ITALY  
 Phone : +39 02.9523.1 - Fax +39 02.9523.5111 e-mail: [info@olonspa.it](mailto:info@olonspa.it) [www.olonspa.com](http://www.olonspa.com)